Show simple item record

dc.contributor.authorCrtaft, Suzanne
dc.contributor.authorAsthana, Sanjay
dc.contributor.authorNewcomer, John W.
dc.contributor.authorWilkinson, Charles W.
dc.contributor.authorTio Matos, Iris
dc.contributor.authorBaker, Laura D.
dc.contributor.authorCherrier, Monique
dc.contributor.authorLofgreen, Cassin
dc.contributor.authorLatendresse, Shawn
dc.contributor.authorPetrova, Andreana
dc.contributor.authorPlymate, Stephen
dc.contributor.authorRaskind, Murray
dc.contributor.authorGrimwood, Karla
dc.contributor.authorVeith, Richard C.
dc.date.accessioned2011-11-23T20:56:56Z
dc.date.available2011-11-23T20:56:56Z
dc.date.issued1999-12
dc.identifier.urihttp://hdl.handle.net/1773/19322
dc.description.abstractBackground: Increasing plasma glucose levels improves memory in patients with Alzheimer disease (AD). Increasing plasma glucose levels also increases endogenous insulin levels, raising the question of whether memory improvement is due to changes in insulin, independent of hyperglycemia. We address this question by examining memory and counterregulatory hormone response during hyperglycemia when endogenous insulin was suppressed by concomitant infusion of the somatostatin analogue octreotide (Sandostatin). Methods: Twenty-three patients with AD and 14 similarly aged healthy adults participated in 4 metabolic conditions on separate days: (1) hyperinsulinemia (538 pmol/L) with fasting glucose (5.6 mmol/L [100 mg/dL]), achieved by insulin and variable dextrose infusion; (2) hyperglycemia (12.5 mmol/L [225 mg/dL]) with fasting insulin (57 pmol/L), achieved by dextrose and somatostatin (octreotide) infusion (150 mg/h); (3) placebo with isotonic sodium chloride solution (saline) infusion (fasting insulin and glucose); and (4) an active control condition in which somatostatin alone was infused (150 mg/h). Declarative memory (story recall) and selective attention (Stroop interference test) were measured during steady metabolic states. Results: Patients with AD showed improved memory during hyperinsulinemia relative to placebo (P = .05) and relative to hyperglycemia (P,.005). Memory did not improve during hyperglycemia when insulin was suppressed. Somatostatin analogue infusion alone also improved memory for patients with AD (P,.05). Hyperinsulinemia increased cortisol levels in subjects with AD, whereas somatostatin alone lowered cortisol concentrations. Conclusions: These results confirm that elevated insulin without hyperglycemia enhances memory in adults with AD, and indicate that insulin is essential for hyperglycemic memory facilitation. These results also suggest a potential therapeutic role for somatostatin in AD.en_US
dc.language.isoen_USen_US
dc.publisherArch.Gen.Psychiatryen_US
dc.titleEnhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucoseen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record